The new Section 232 tariffs on pharmaceuticals raise broader legal, compliance, and supply chain considerations for companies operating in this sector. This webinar will examine what these measures may mean for manufacturers, importers, and downstream market participants. Our speaker will discuss the practical challenges companies may face in assessing exposure, managing compliance risk, and planning for operational disruption, as well as what steps companies can take to respond.
About The Webinar
Key Topics
- Explanation of the new Section 232 tariffs on pharmaceuticals
- Key compliance and reporting considerations triggered by Section 232 trade actions
- Compliance considerations for companies navigating heightened trade and enforcement scrutiny
Speaker 

Andrea K. Jeglum Associate
Andrea K. Jeglum Associate
ANDREA K. JEGLUM is an associate with Sandler, Travis & Rosenberg, P.A., located in the Boston area. She concentrates her practice on customs compliance matters including tariff classification, country of origin, valuation, trade agreements, foreign-trade zones, and duty reduction programs. She also helps clients meet U.S. requirements concerning trade in biopharma, agro-chemicals, and animal products, including endangered species, as well as export filings and enforcement measures.
Other Webinars from Andrea K. Jeglum
-
On Demand
Learn MoreBiopharma & Life Sciences Clinical Trial Valuation for U.S. Customs Purposes
Customs Valuation -
On Demand
Learn MoreUnderstanding U.S. Customs Valuation in the Biopharma and Life Sciences Industry
Customs & Import Compliance -
On Demand
Learn MoreUsing the Prototype Provision for Duty Savings
Tariff Classification, Tariff Engineering & Chapter 98 Provisions
Contact Us